Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Catalyst Pharmaceuticals received mixed reviews from different experts. While the company has successfully launched their third drug and has seen increasing revenues, there are concerns about the high cost of their drug for rare diseases and the limited market due to the small number of people affected. Additionally, the company's recent share offering led to a drop in shares, and there is uncertainty about their future due to changes in leadership and doubts about their business model. Some experts believe the company may be taken over due to the hot market for rare disease companies, but others have advised against investing in this stock, citing better options in the same industry.

Consensus
Mixed
Valuation
Fair Value
BUY

A top biotech though it took him a while to like this, but they successfully launched their third drug last month. Good, because the first two drugs go off-patent soon.

biotechnology
DON'T BUY

A biopharma that develops for rare diseases, such as LEMS for which CPRX's drug has received approval. But this trip costs US$360,000. Only insurance allows CPRX to charge such prices; revenues have been rising. But there's a ceiling, because there are a limited number of people afflicted with this disease. They bought US rights for the drug Fycompa, and bought a company that makes aGamree to treat another rare disease. An analyst believes the latter drug and feels shares can double. However, the firm Oppenheimer said that CPRX didn't need the money, and then the same firm was listed as a co-manager for a recent share offering. Result: shares dropped 15%. Last year, the CEO retired, and the CFO stepped down, so he thought CPRX may be sold, but the offering throws doubt on that. That said, rare disease companies are hot and so CPRX could be taken over. He doesn't like their business model: buying other companies and their drugs instead of developing their own. And their two drugs have patent protection for only a few more years--bad. There are better stocks in this space.

biotechnology
BUY

Should be higher. They make a lot of money and beat their quarter.

biotechnology
Showing 1 to 3 of 3 entries
  • «
  • 1
  • »

Catalyst Pharmaceuticals(CPRX-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Catalyst Pharmaceuticals is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Catalyst Pharmaceuticals(CPRX-Q) Frequently Asked Questions

What is Catalyst Pharmaceuticals stock symbol?

Catalyst Pharmaceuticals is a American stock, trading under the symbol CPRX-Q on the NASDAQ (CPRX). It is usually referred to as NASDAQ:CPRX or CPRX-Q

Is Catalyst Pharmaceuticals a buy or a sell?

In the last year, 2 stock analysts published opinions about CPRX-Q. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Catalyst Pharmaceuticals.

Is Catalyst Pharmaceuticals a good investment or a top pick?

Catalyst Pharmaceuticals was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Catalyst Pharmaceuticals.

Why is Catalyst Pharmaceuticals stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Catalyst Pharmaceuticals worth watching?

2 stock analysts on Stockchase covered Catalyst Pharmaceuticals In the last year. It is a trending stock that is worth watching.

What is Catalyst Pharmaceuticals stock price?

On 2024-07-15, Catalyst Pharmaceuticals (CPRX-Q) stock closed at a price of $16.76.